Active Biotech Logo

Active Biotech

ISIN

SE0001137985

Ticker

ACTI

Sector

Health Care

Sub-Industry

Biotechnology

Country

Sweden

Year Founded

1998

About Active Biotech

Company Description

Active Biotech develops pharmaceutical products within medical areas where the immune system is of significant importance, including cancer and inflammatory diseases. The project portfolio comprises both small, orally active immunomodulatory molecules and antibody-based immunotherapy.

Active Biotech has its base in Lund, Sweden and was formed in 1998 as a spin-off from Pharmacia & Upjohn. The share is listed and traded on Nasdaq Stockholm (Small Cap). The Company has core competence in cancer and inflammatory diseases and a competent team with extensive experience in drug development from early to late stage clinical development.

Headquarters

Scheelevägen 22
22363, Lund
Sweden

Financial statements

Download as Excel
Line item in (sek) 02.01.2020 01.01.2021 02.01.2021 01.01.2022 02.01.2022 01.01.2023
Assets N/A 32,155,000.00 N/A 56,804,000.00 N/A 51,005,000.00
Noncurrent Assets N/A 1,871,000.00 N/A 946,000.00 N/A 6,885,000.00
Noncurrent Receivables N/A 1,000.00 N/A 1,000.00 N/A 376,000.00
Current Assets N/A 30,284,000.00 N/A 55,858,000.00 N/A 44,120,000.00
Current Trade Receivables N/A 284,000.00 N/A 0.00 N/A N/A
Current Prepayments And Current Accrued Income Other Than Current Contract Assets N/A N/A N/A 1,534,000.00 N/A 1,377,000.00
Current Tax Assets Current N/A 739,000.00 N/A 739,000.00 N/A 600,000.00
Cash and cash equivalents 59,681,000.00 26,213,000.00 26,213,000.00 53,134,000.00 53,134,000.00 41,796,000.00
Equity And Liabilities N/A 32,155,000.00 N/A 56,804,000.00 N/A 51,005,000.00
Equity 53,783,000.00 22,113,000.00 22,113,000.00 46,674,000.00 46,674,000.00 34,511,000.00
Issued Capital N/A 750,000.00 N/A 1,126,000.00 N/A 1,368,000.00
Retained Earnings N/A -3,290,505,000.00 N/A -3,340,047,000.00 N/A -3,397,729,000.00
Additional Paidin Capital N/A 3,311,868,000.00 N/A 3,385,595,000.00 N/A 3,430,872,000.00
Liabilities N/A 10,042,000.00 N/A 10,130,000.00 N/A 16,494,000.00
Noncurrent Liabilities N/A 689,000.00 N/A 226,000.00 N/A 4,432,000.00
Current Liabilities N/A 9,353,000.00 N/A 9,904,000.00 N/A 12,062,000.00
Trade And Other Current Payables To Trade Suppliers N/A 2,852,000.00 N/A 2,761,000.00 N/A 3,528,000.00
Current Accruals And Current Deferred Income Including Current Contract Liabilities N/A N/A N/A 6,128,000.00 N/A 6,692,000.00
Other Current Payables N/A 219,000.00 N/A 255,000.00 N/A 236,000.00
Line item in (sek) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 6,725,000.00 0.00 0.00
Profit Loss From Operating Activities -32,306,000.00 -49,782,000.00 -57,886,000.00
Finance Income 215,000.00 15,000.00 49,000.00
Finance Costs 154,000.00 58,000.00 535,000.00
Profit Loss Before Tax -32,245,000.00 -49,825,000.00 -58,372,000.00
Income Tax Expense Continuing Operations 0.00 0.00 0.00
Profit (loss) -32,245,000.00 -49,825,000.00 -58,372,000.00
Profit Loss Attributable To Owners Of Parent -32,245,000.00 -49,825,000.00 -58,372,000.00
Profit Loss Attributable To Noncontrolling Interests 0.00 0.00 0.00
Line item in (sek) 01.01.2021 02.01.2020 01.01.2022 02.01.2021 01.01.2023 02.01.2022
Profit (loss) -32,245,000.00 N/A -49,825,000.00 N/A -58,372,000.00 N/A
Adjustments For Reconcile Profit Loss 1,896,000.00 N/A 1,562,000.00 N/A 2,185,000.00 N/A
Adjustments For Reconcile Profit Loss 1,896,000.00 N/A 1,562,000.00 N/A 2,185,000.00 N/A
Cash Flows From Used In Operating Activities -32,216,000.00 N/A -46,166,000.00 N/A -54,850,000.00 N/A
Purchase Of Intangible Assets Classified As Investing Activities N/A N/A 0.00 N/A 245,000.00 N/A
Cash Flows From Used In Investing Activities N/A N/A 0.00 N/A -245,000.00 N/A
Proceeds From Issuing Shares 0.00 N/A 76,249,000.00 N/A 46,832,000.00 N/A
Payments Of Lease Liabilities Classified As Financing Activities 1,252,000.00 N/A 1,015,000.00 N/A 1,762,000.00 N/A
Cash Flows From Used In Financing Activities -1,252,000.00 N/A 73,087,000.00 N/A 43,757,000.00 N/A
Effect Of Exchange Rate Changes On Cash And Cash Equivalents 0.00 N/A 0.00 N/A 0.00 N/A
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes -33,468,000.00 N/A 26,921,000.00 N/A -11,338,000.00 N/A
Cash and cash equivalents 26,213,000.00 59,681,000.00 53,134,000.00 26,213,000.00 41,796,000.00 53,134,000.00

Please note that some sums might not add up.

Filings & Publications

  • Consolidated Report 2022 - Q4 Swedish 🇸🇪 Published: 09.05.2023
  • Consolidated Report 2021 - Q4 Swedish 🇸🇪

Insider Trades

Date Trading entity / Person Association Trade type Volume
05.09.2022 Aleksandar Danilovski Other Buy SEK 26,672.00
22.04.2022 Helen Tuvesson Andersson Other Buy SEK 3,102.86
21.04.2022 Helen Tuvesson Andersson Other Buy SEK 41,767.60
17.06.2021 Aleksandar Danilovski Other Buy SEK 60,000.00
01.06.2021 Michael Shalmi Other Buy SEK 259,437.50
27.04.2021 Helen Tuvesson Andersson Other Buy SEK 16,657.60
27.04.2021 Helena Eriksson Other Buy SEK 14,460.00
27.04.2021 Helen Tuvesson Andersson Other Buy SEK 1,665.60
26.04.2021 Helen Tuvesson Andersson Other Buy SEK 13,961.58
26.04.2021 Peter Thelin Other Other SEK 0.00

Capital Markets Information

ISIN

SE0001137985

LEI

549300OJ44CLMRU8YE43

Sub-Industry

Biotechnology

Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations Department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.